Skip to content

Sodium Valproate and Diabetic nephropathy

Assess the effectiveness of Sodium valproate on level of albuminuria in patient with type 2 diabetes :A double-blind randomized clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20201023049126N1
Enrollment
60
Registered
2021-03-30
Start date
2021-02-19
Completion date
Unknown
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nephropathy. Type 2 diabetes mellitus with diabetic nephropathy

Interventions

Intervention 1: Intervention group1:twenty patients take sodium valproate 200 mg tablet of Destin company daily for 3 months. Intervention 2: Intervention group2: twenty patients take sodium valproate

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: patients with DMTII albuminuria more than 30mg/dl

Exclusion criteria

Exclusion criteria: Allergy to valproic acid Significantly abnormal liver function test A history of known mental disorders History of cardiac or liver diseases Females who were lactating, pregnant, or intending to become pregnant during the study. A current history of alcohol addiction or drug abuse including analgesics abnormal blood cells counts eGFR less than 60 ml/min/1.73m2 hemoglobin A1c more than 8 Blood Pressure more than 160/100 mmHg neurologic disease such as seizure use antidepressant or antipsychotic drugs History of GN, renal stone or other renal disease that induced proteinuria active hematologic, rheumatologic or infectious diseases active cancers or tumors uncontrol hypo or hyper thyroidism uncontrol hyper parathyroidism

Design outcomes

Primary

MeasureTime frame
Microalbuminuria. Timepoint: At the beginning of the study, one month, two months and three months after starting the drug. Method of measurement: Measurement of microalbuminuria of urine samples.

Secondary

MeasureTime frame
Liver function test. Timepoint: At the beginning of the study, one month, two months and three months after starting the drug. Method of measurement: Using the patient's blood sample.;Complete blood count. Timepoint: At the beginning of the study, one month, two months and three months after starting the drug. Method of measurement: Using the patient's blood sample.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Alireza Zomorodian

Shiraz University of Medical Sciences

mil.zomorod@gmail.com+98 71 3208 4045

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026